Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Ocrelizumab
Monoclonal Antibody · Agent for Multiple Sclerosis
Monoclonal AntibodyAgent for Multiple Sclerosis
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risklimited information available; monitor infants for B-cell depletion.
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Ocrelizumab works by binding CD20 on B and pre-B lymphocytes followed by antibody-dependent cellular cytotoxicity and complement-mediated lysis of CD20+ cells. Since this is a B cell-depleting Mab, patients should be monitored for increased risk of infection.
Indications
Multiple sclerosis (specialist use only)Relapsing multiple sclerosisPrimary progressing multiple sclerosismsrelapsing-remitting mssecondary progressive msprimary progressive ms
Dosing
- Adult
- Initially 300 mg via intravenous infusion, then 300 mg after 2 weeks; maintenance 600 mg every 6 months, the first maintenance dose should be given 6 months after the first initial dose; a minimum interval of 5 months should be maintained between each maintenance dose, for dose interruption, adjustment of infusion rate or discontinuation of treatment due to infusion-related reactions or side-effec…
Contraindications
- Active infection
- Active malignancies
- Severely immunocompromised patients
Side effects
Common
CatarrhIncreased risk of infectionUpper respiratory tract infections
Serious
- Malignancy
- Progressive multifocal leucoencephalopathy (PML)
- Hepatitis B reactivation
- slight increase in infections
Pregnancy & lactation
Pregnancy
Manufacturer advises avoid unless potential benefit outweighs risklimited information available; monitor infants for B-cell depletion.
Lactation
Manufacturer advises avoidpresent in milk in animal studies.
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Measles Virus Vaccine Live Attenuated
Severe
Database
Clinical effect not specified
Source: DDInter
Mumps Virus Strain B Level Jeryl Lynn Live Antigen
Severe
Database
Clinical effect not specified
Source: DDInter
Natalizumab
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Primary PCI for acute coronary syndrome
ESC · Cardiology · 2026
Stroke and TIA — secondary prevention
AHA · Neurology · 2021
Acute jaundice — adult primary care
MOHFW · Gastroenterology · 2021
Primary headache disorders
NICE · Neurology · 2021
Primary prevention of cardiovascular disease
AHA · Cardiology · 2019
Other Monoclonal Antibody drugs
Ask House about Ocrelizumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-13 · House clinical team